Connect your AI

AptarGroup ATR Cumulative Cost Basis

Cumulative Cost Basis at other companies

West Pharmaceutical ServicesWST

——

Halozyme TherapeuticsHALO

——

Becton, Dickinson and CompanyBDX

——

DoverDOV

——

International Flavors & FragrancesIFF

——

ViatrisVTRS

——

Other financials

Income statement

Revenue$982.9M+10.8%

Gross profit$351.9M+4.6%

Operating income$107.5M-5.2%

Net income$72.7M-7.8%

EPS (diluted)$1.12-4.3%

Balance sheet

Cash & equivalents$225.0M+78.8%

Total debt$1.4B+32.7%

Total equity$2.6B+3.6%

Total assets$5.1B+12.6%

Cash flow

Operating cash flow$118.7M+43.5%

CapEx$65.4M+15.0%

Free cash flow$53.3M+106%

Valuation

Market cap$7.68B-17.9%

Enterprise value$8.89B-13.9%

P/E19.9×-5.4×

P/S2×-0.6×

Profitability

Gross margin36.7%-1.6pp

Operating margin12.8%-1.2pp

Net margin10%-0.4pp

FCF margin8.4%-2.1pp

Returns & leverage

Return on equity15%-0.2pp

Debt / equity0.5×+0.1×

Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept us-gaap:RestructuringAndRelatedCostCostIncurredToDate1.

The official record: AptarGroup’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about AptarGroup's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is AptarGroup's cumulative cost basis?: AptarGroup (ATR) reported cumulative cost basis of $75.6M in Q1 2026.